TAIPEI and SAN DIEGO , Nov. 1, 2024 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the appointment of Dr.
Yiu-Lian Fong to the board of directors for Ding Li Development Ltd. Dr. Fong, a present member of the Bio Taiwan Committee (BTC) under the Executive Yuan since 2020, has served various organizations in Taiwan including the BTC, the Ministry of Science and Technology Council, and the Medical Device Innovation Center, NCKU as an expert consultant since 2017 to help drive the growth of Biotech industry.
Dr. Fong previously served as the Global Head, Diagnostic Innovation and R&D and Clinical Biomarker Strategy and Development at Janssen, Johnson & Johnson. Having nearly thirty years of successful R&D leadership experience for new drug discovery and development in the global pharmaceutical companies, Dr.
Fong is dedicated to addressing unmet medical needs for major diseases such as cancer. Her versatile experiences will provide valuable insights into Senhwa's strategic approaches to developing new drugs, help accelerate development timelines, and position Senhwa for the global market. Dr.
Fong received her PhD at Vanderbilt University and completed her post-doctoral training at the Johns Hopkins University. She held important and progressive leadership positions in various global pharmaceutical and IVD companies. She advanced from s.